What is the Fiscal Year for Intellia Therapeutics?
Date: November 13, 2026
Intellia Therapeutics's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q4, which ends on December 31, 2026.
Current Fiscal Year Overview
Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q4
Current Quarter End
December 31, 2026
Quarterly Breakdown
Q1
Jan 1, 2026 – Mar 31, 2026
Q2
Apr 1, 2026 – Jun 30, 2026
Q3
Jul 1, 2026 – Sep 30, 2026
Q4
Oct 1, 2026 – Dec 31, 2026
Company Information
Headquarters
Cambridge, Massachusetts
Industry
Biotechnology Research
Stock Symbol
NTLA
Website
http://www.intelliatx.comDescription
Intellia Therapeutics is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. We are employing our proprietary technologies to create diverse therapeutic approaches spanning a range of diseases to realize Intellia’s full potential and address the needs of patients globally. View our social media community guidelines at https://www.intelliatx.com/terms-and-conditions/. Intellia Therapeutics, and the Intellia Therapeutics logo are trademarks of Intellia Therapeutics, Inc., registered in the U.S. Patent and Trademark Office and other jurisdictions. © 2026. Intellia Therapeutics, Inc.
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Intellia Therapeutics and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.
